Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCL161 plus Paclitaxel in TNBC
NCT01617668Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2012
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of LCL161 in triple-negative breast cancer (TNBC), sponsored by Novartis. Started Aug 2012; status: completed.
02
Drugs
LCL161
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01617668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01617668.